Macquarie Group Ltd. grew its stake in Sanofi (NYSE:SNY) by 1.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,622,391 shares of the company’s stock after purchasing an additional 29,045 shares during the quarter. Macquarie Group Ltd. owned approximately 0.10% of Sanofi worth $130,569,000 as of its most recent filing with the SEC.
Other institutional investors also recently modified their holdings of the company. Fisher Asset Management LLC raised its stake in shares of Sanofi by 3.3% in the 3rd quarter. Fisher Asset Management LLC now owns 14,082,257 shares of the company’s stock valued at $701,156,000 after purchasing an additional 443,799 shares in the last quarter. Founders Financial Securities LLC acquired a new stake in shares of Sanofi in the 2nd quarter valued at about $907,000. Goodwin Daniel L acquired a new stake in shares of Sanofi in the 2nd quarter valued at about $239,000. AMG National Trust Bank raised its stake in shares of Sanofi by 5.3% in the 2nd quarter. AMG National Trust Bank now owns 51,423 shares of the company’s stock valued at $2,464,000 after purchasing an additional 2,594 shares in the last quarter. Finally, Alethea Capital Management LLC acquired a new stake in shares of Sanofi in the 3rd quarter valued at about $794,000. Institutional investors and hedge funds own 9.13% of the company’s stock.
Several equities research analysts recently weighed in on SNY shares. Zacks Investment Research lowered shares of Sanofi from a “hold” rating to a “strong sell” rating in a research note on Friday, October 6th. Morgan Stanley lowered shares of Sanofi from an “overweight” rating to an “underweight” rating in a research note on Friday. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Sanofi in a research note on Friday, September 15th. Barclays upgraded shares of Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Wednesday, November 15th. Finally, BidaskClub upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $53.50.
COPYRIGHT VIOLATION WARNING: This article was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://weekherald.com/2017/12/04/sanofi-sny-shares-bought-by-macquarie-group-ltd.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.